Search results for "OTHER"

showing 10 items of 12132 documents

Natural history of congestive gastropathy in cirrhosis

1990

In a prospective study of the natural history of congestive gastropathy, 212 consecutive cirrhotic patients (75 treated with sclerotherapy) were included. Mean follow-up was 46 months. Mild gastropathy (mosaiclike pattern) was found in 110 patients and severe gastropathy (granular mucosa with cherry spots) was found in 20. Prevalence of Helicobacter pylori, formerly Campylobacter pylori, was 50% in patients without, 43% in those with mild, and 28% in those with severe gastropathy. Congestive gastropathy was significantly more frequent in patients treated with sclerotherapy (83% vs. 50%, P less than 10(-5)). Sixty-month actuarial proportions of patients free of anemia (in the absence of hema…

medicine.medical_specialtyCirrhosisHepatologyAnemiabusiness.industrymedicine.medical_treatmentGastroenterologyPortal hypertensive gastropathymedicine.diseaseGastroenterologyEsophageal varicesMelenaInternal medicinemedicineSclerotherapymedicine.symptomVaricesComplicationbusinessGastroenterology
researchProduct

Response of patients with chronic Hepatitis B in one year of treatment with Major Autohemotherapy.

2018

The Hepatitis B (HVB) is one of the most common infectious diseases in the world, it’s wide geographical distribution is a health problem, especially on the African continent, with prevalence rate of 6.1% in the adult population. Current treatment requires prolonged therapy (most cases for the rest of life) with the aim of stopping viral replication, maintaining immunological stability, preventing progression of liver disease and the most feared complications such as cirrhosis and hepatic cancer
 There are multiple references that point to ozone therapy as an alternative in the treatment of Hepatitis B, because of the known and demonstrated antimicrobial and immunomodulatory properties…

medicine.medical_specialtyCirrhosisbiologybusiness.industryHepatitis B:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseOzone therapyGastroenterologyAutohemotherapyLiver diseaseAntigenInternal medicineUNESCO::CIENCIAS MÉDICASmedicinebiology.proteinAntibodybusinessViral loadJournal of Ozone Therapy
researchProduct

The necessity of placebo application in psychotropic drug trials.

1990

medicine.medical_specialtyClinical Trials as TopicPsychotropic DrugsPsychotherapistMEDLINEGeneral MedicinePlaceboClinical trialPlacebosPsychiatry and Mental healthPsychotropic drugmedicineHumansPharmacology (medical)PsychopharmacologyPsychiatryPsychologyDepression (differential diagnoses)Randomized Controlled Trials as TopicPharmacopsychiatry
researchProduct

A methodological framework to enhance the clinical success of cancer immunotherapy.

2011

medicine.medical_specialtyClinical Trials as Topicbusiness.industrymedicine.medical_treatmentPublicationsBiomedical EngineeringBioengineeringGuidelines as TopicApplied Microbiology and BiotechnologyClinical successSurvival AnalysisText miningTreatment OutcomeCancer immunotherapyNeoplasmsBiomarkers TumorMolecular MedicineMedicineHumansMedical physicsCTLA-4 AntigenImmunotherapybusinessBiotechnologyNature biotechnology
researchProduct

International prescribing practices in obsessive-compulsive disorder (OCD)

2016

Objectives To assess rates of psychotropic medication use in patients with obsessive–compulsive disorder (OCD) in seven different countries on five continents and to compare these with international treatment guidelines. Methods Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their patients with OCD and on their incidence of psychotropic use. Consistency of summary statistics across countries was evaluated. Results The data came from Brazil (n = 955), Italy (n = 750), South Africa (n = 555), Japan (n = 382), Australia (n = 213), India (n = 202) and Spain (n = 82). The majority (77.9%; n = 2445) of the total sample of 3139 participants …

medicine.medical_specialtyClomipraminemedicine.drug_classbusiness.industryIncidence (epidemiology)Atypical antipsychoticPsychotropic medicationmedicine.disease030227 psychiatry03 medical and health sciencesPsychiatry and Mental health0302 clinical medicinePharmacotherapyNeurologymedicinePharmacology (medical)In patientNeurology (clinical)PsychiatrybusinessProspective cohort studyObsessive-compulsive disorder (OCD)030217 neurology & neurosurgerymedicine.drugHuman Psychopharmacology: Clinical and Experimental
researchProduct

Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers

2015

AbstractFluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) has become a routine imaging modality for many malignancies and its use is currently increasing. In the present review article, we will summarize the evidence for FDG-PET/CT use in digestive cancers (excluding neuroendocrine tumours), and review the existing recommendations. While PET/CT is nowadays considered to be an important tool in the initial workup of oesophageal and anal cancers, new data are emerging regarding its use in assessing therapeutic efficacy, radiotherapy treatment planning, and detection of recurrence in case of isolated tumour marker elevation. Moreover, PET/CT may help …

medicine.medical_specialtyColorectal cancerColonoscopyDigestive System NeoplasmsMultimodal ImagingPatient Care PlanningFluorodeoxyglucose positron emission tomographyFluorodeoxyglucose F18Pancreatic cancerHumansMedicinePositron Emission Tomography-Computed TomographyFluorine-18-fluorodeoxyglucoseHepatologymedicine.diagnostic_testbusiness.industryOesophageal cancerGastroenterologyPancreatic cancerRadiotherapy treatment planningPrognosismedicine.diseaseColorectal cancerFDG-PET/CTAnal canal cancerReview articleNeuroendocrine TumorsPositron-Emission TomographyPractice Guidelines as TopicRadiologyNeoplasm Recurrence LocalRadiopharmaceuticalsTomography X-Ray ComputedbusinessDigestive and Liver Disease
researchProduct

Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colore…

2020

International audience; BACKGROUND: Regorafenib significantly increases overall survival (OS) in patients with metastatic colorectal cancer previously treated but gives toxicities. OBJECTIVES: to assess the efficacy and safety of regorafenib at it's approved dose in the older population. PATIENTS AND METHODS: This multicenter single-arm phase II enrolled patients ≥70 years old after the failure of fluoropyrimidine-based chemotherapy, anti-VEGF, and anti-EGFR treatment. The primary endpoint was disease control rate (DCR) 2 months after initiation of regorafenib (160 mg/day, 3 weeks on/1 week off). RESULTS: Forty-three patients were enrolled, with a median age of 77 years. The 2 months DCR wa…

medicine.medical_specialtyColorectal cancerPyridinesmedicine.medical_treatment[SDV]Life Sciences [q-bio]AdenocarcinomaGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineQuality of lifeRegorafenibInternal medicinemedicineClinical endpointHumans030212 general & internal medicineAdverse effectChemotherapybusiness.industryPhenylurea Compoundsmedicine.disease3. Good health[SDV] Life Sciences [q-bio]DiarrheaOncologychemistry030220 oncology & carcinogenesisToxicityQuality of LifeGeriatrics and Gerontologymedicine.symptombusinessColorectal Neoplasms
researchProduct

Management of rectal cancer in France in a well-defined population.

2014

Objective The aim of this study was to draw a picture of diagnostic assessment and patterns of care for rectal cancer in France using population-based registries data. Methods The study included a random sample of 669 cases of rectal cancers diagnosed in 2005. Results Diagnostic assessment was performed by colonoscopy in 91.4% of the cases. An abdominal computed tomography was performed in 59.4% of the cases and chest computed tomography in 47.8%. An R0 resection was performed in 65.8% of cases and an R1/R2 resection in 16.1%. A rectal endosocography was performed in 40.4% and MRI in 10.4%. The sphincter was preserved in 73.6% of patients aged younger than 75 years of age and in 62.5% of th…

medicine.medical_specialtyColorectal cancermedicine.medical_treatmentPopulationColonoscopyAnal CanalPreoperative carePreoperative CaremedicineHumansRegistriesStage (cooking)educationAgedNeoplasm Stagingeducation.field_of_studyHepatologymedicine.diagnostic_testbusiness.industryRectal NeoplasmsPalliative CareGastroenterologyAge FactorsChemoradiotherapy AdjuvantColonoscopymedicine.diseaseRadiation therapymedicine.anatomical_structureSphincterRadiologyFrancebusinessTomography X-Ray ComputedChemoradiotherapyEuropean journal of gastroenterologyhepatology
researchProduct

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.

2013

Contains fulltext : 118153.pdf (Publisher’s version ) (Open Access) Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted dr…

medicine.medical_specialtyCombination therapyPharmacologyAntiviral AgentsDrug interactionsTelaprevirTelaprevirchemistry.chemical_compoundPharmacotherapyAnti-Infective AgentsBoceprevirOpiate Substitution TreatmentmedicineHumansHypnotics and SedativesHypoglycemic AgentsPharmacokineticsSummary of Product CharacteristicsIntensive care medicineAdverse effectPolypharmacyBoceprevirHepatologybusiness.industryHCV therapyCardiovascular AgentsHepatitis C ChronicAntidepressive AgentsBuprenorphinechemistryCardiovascular agentHepatitis C virus infectionDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsPoverty-related infectious diseases Infectious diseases and international health [N4i 3]businessImmunosuppressive AgentsMethadonemedicine.drug
researchProduct

The use of combination therapy with 20% glycolic acid and fractional mesotherapy to reduce acne scars: a case repor

2019

Background: Acne scars are a common problem for those suffering from acne vulgaris. They may result in low self-esteem, especially if located in visible places such as the face. They may even impede normal societal functioning and withdrawal from the environment. Aim of the study: To investigate the effects of 20% glycol acid and fractional mesotherapy on the reduction of acne scars. Material and methods: We used interviews, case analysis and assessment of the effects of glycolic acid treatment and fractional mesotherapy on a 33-year-old female patient who experienced severe phlegmonosa acne. Case report: This 33-year-old female patient was struggling with acne at age 29. Purulent cysts wer…

medicine.medical_specialtyCombination therapybusiness.industryfractional mesotherapyDermatologyMesotherapy030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisAHAmedicinescarsAcne scarsbusinessGlycolic acidMedical Science Pulse
researchProduct